title: [Efficacy and future of the aerosoltherapy in the treatment of cystic fibrosis patients infected by Pseudomonas aeruginosa].
abstract: Pseudomonas aeruginosa is considered as the most redoubtable pathogenic           agent at cystic fibrosis patients. Its eradication is a priority to avoid the passage to           chronic infection, the real turning point of the disease. For this, a wide therapeutic           panel of intravenous antibiotics exists, and for some years, the research teams           concentrate more and more on the inhaled way. The synthesis of the literature data           presented herein focuses on both already experienced molecules (colistin and tobramycin),           and on new therapeutics. This review aims at loosening advantages and inconveniences of           each of these therapeutic options, while bringing to light the necessity of follow-up           studies in order to prove the therapeutic interests of molecules in development.
authors.affiliation: Service Central de la Qualité et de l'Information Pharmaceutique, Assistance Publique des Hôpitaux de Marseille, Marseille, France.
authors.forename: Amélie
authors.initials: A
authors.lastname: Rognon
authors.forename: Christophe
authors.initials: C
authors.lastname: Curti
authors.forename: Marc
authors.initials: M
authors.lastname: Montana
authors.forename: Thierry
authors.initials: T
authors.lastname: Terme
authors.forename: Pascal
authors.initials: P
authors.lastname: Rathelot
authors.forename: Patrice
authors.initials: P
authors.lastname: Vanelle
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D000583:Amikacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D003091:Colistin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000150:complications*; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D014031:Tobramycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000336:Aerosols; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D002939:Ciprofloxacin; D000583:Amikacin; D014031:Tobramycin; D003091:Colistin